How to treat gastroesophageal adenocarcinom patients?

	Tweet

Gastroesophageal adenocarcinomas have a poor prognosis. However, numerous randomized clinical trials (RCT) have evaluated, and continue to evaluate, the survival benefit of various treatment regimens. Surgery remains standard care for early stage esophageal cancer and gastric cancer. However, RCTs have also shown a survival benefit associated with chemotherapy and chemoradiation. Few studies have examined community-based patterns of care for these cancers. A study of esophageal adenocarcinoma and squamous cell carcinoma patients diagnosed between 1996 and 1999 found that chemoradiation without surgery was most frequent therapy, although patients given chemoradiation followed by surgery had better survival compared to chemoradiation alone. Research suggests community-based use of treatment and the observed survival of patients in the community can vary depending on clinical and non-clinical factors.

A research study to be published on 28 May 2008, in the World Journal of Gastroenterology investigates treatments received and factors that influence the receipt of treatment in gastroesophageal adenocarcinoma.

The study findings indicate the relatively low use of RCT-approved treatments in US community-based practice despite their demonstrated survival benefits.

Investigators report lower mortality among patients with esophageal and stomach adenocarcinoma who received chemotherapy and significant disparities in terms of age in treatment receipt. The findings indicate that US community physicians take an individualized approach in treating adenocarcinoma of the esophagus, gastric cardia, and stomach; differentiating gastroesophageal adenocarcinoma as two distinct entities (i.e., esophageal and stomach) and use different treatment strategies and chemotherapeutic agents for each, while patients with gastric cardia adenocarcinoma are treated with a mixture of agents employed for the other two anatomic sites. The study concludes that improvements in community-based treatment of gastroesophageal adenocarcinoma will require better differentiation of treatments by anatomic sites and more extensive incorporation of those treatments proven effective in clinical trials.

Future RCTs should be designed and appropriately powered to account for differences related to the anatomic site or origin of the tumor as well as the underlying tumor biology.

###

Contact: Lai-Fu Li

86-105-908-0039
World Journal of Gastroenterology

RELATED STORIES:
Can Cancer of the Esophagus Be Prevented?   3-D model of esophageal cancer   Gene Variations Alter Risk of Esophageal Cancer   Alcohol type linked to Barrett’s esophagus risk   Is increased Slug expression associated with the progression to esophageal cancer?   Barrett’s Esophagus Patients Have Same Survival Rates as General Population   How is cancer of the esophagus diagnosed?   Daily drinking may raise risk of several cancers   What Are the Key Statistics About Cancer of the Esophagus?   Minimally-Invasive Treatment Found Effective for Esophageal Cancer   Wine may cut risk of esophagus pre-cancer   UNC Researcher to Help Lead New Esophageal Cancer Network   Esophageal Cancer Overview of Prevention   Acid reflux may raise risk of cancer of larynx   What are the side effects of treatment for cancer of the esophagus?   Osteoporosis Drugs do not Increase Risk of Esophageal Cancer   Esophageal cancer surgery not affected by obesity   H. Pylori Bacteria May Help Prevent Some Esophageal Cancers   What Is Cancer of the Esophagus?   Researchers use sugar to halt esophageal cancer in its tracks   A biotherapy strategy for esophageal cancer in the future   Esophageal cancer risk higher in medically treated GERD patients with fewest symptoms

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]